汉森制药8月27日获融资买入1520.10万元，融资余额1.44亿元

Core Viewpoint - Hansen Pharmaceutical experienced a decline of 4.18% in stock price on August 27, with a trading volume of 131 million yuan, indicating potential market volatility and investor sentiment concerns [1] Financing Summary - On August 27, Hansen Pharmaceutical had a financing buy-in amount of 15.20 million yuan and a financing repayment of 15.99 million yuan, resulting in a net financing buy of -0.797 million yuan [1] - The total financing and securities balance for Hansen Pharmaceutical as of August 27 is 144 million yuan, which accounts for 4.30% of its circulating market value, indicating a relatively high financing level compared to the past year [1] - The company had no short-selling activity on August 27, with a short-selling balance of 0.00 shares, suggesting a lack of bearish sentiment among investors [1] Company Overview - Hansen Pharmaceutical, established on January 21, 1998, and listed on May 25, 2010, is located in Yiyang City, Hunan Province, and specializes in the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations [2] - The company's main revenue sources include: Si Mo Tang Oral Liquid (54.81%), Tian Ma Xing Nao Capsules (23.38%), and other products, with the top three products contributing significantly to total revenue [2] - As of July 31, the number of shareholders increased by 1.15% to 24,400, while the average circulating shares per person decreased by 1.13% to 20,388 shares [2] Financial Performance - For the first half of 2025, Hansen Pharmaceutical reported a revenue of 509 million yuan, reflecting a year-on-year growth of 5.91%, while the net profit attributable to shareholders decreased by 31.80% to 68.54 million yuan [2] - The company has distributed a total of 485 million yuan in dividends since its A-share listing, with 151 million yuan distributed over the past three years [3]